SEC Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, filed a Form 8-K dated December 11, 2023 under Item 8.01 to announce initial data from its ongoing ORIC-533 Phase 1 dose-escalation trial in patients with relapsed/refractory multiple myeloma. The data were presented at the 65th American Society of Hematology Annual Meeting.
Financial and Operating Metrics
The filing text provided does not include revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics. It also does not provide the clinical-trial data referenced in the accompanying press release.
Material Changes Versus Prior Period
No financial or operational comparison with a prior period is provided. The material disclosed event is the release of initial ORIC-533 clinical data from an ongoing Phase 1 trial.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, an updated corporate outlook, specific risk disclosures, contingencies, or details regarding the efficacy, safety, enrollment, or next steps for the ORIC-533 trial. The referenced Exhibit 99.1 press release is not included in the provided filing text.
Facts for Investors to Verify
- Review Exhibit 99.1 for the initial ORIC-533 Phase 1 clinical results and related management commentary.
- Verify the number of patients evaluated, dose levels, response outcomes, durability, safety findings, and trial follow-up period.
- Assess any stated development milestones, planned expansion or combination studies, and expected timing of future data.
- Review the company’s latest periodic filing for cash resources, operating expenses, liquidity runway, financing needs, and risk factors.